Recombinant Human Tissue-type plasminogen activator (PLAT), partial

Code CSB-EP018120HU
Size $224
Order now
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Greater than 90% as determined by SDS-PAGE.
Target Names
Uniprot No.
Research Area
Alternative Names
Alteplase; DKFZp686I03148; Plasminogen activator tissue; Plasminogen activator tissue type; PLAT; Reteplase; t PA; T Plasminogen Activator; t-PA; T-plasminogen activator; Tissue plasminogen activator (t PA); Tissue type plasminogen activator; Tissue-type plasminogen activator chain B; tPA; TPA_HUMAN; TPA1
Homo sapiens (Human)
Expression Region
Target Protein Sequence
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
Protein Length
Tag Info
N-terminal 6xHis-SUMO-tagged
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.

The production of this recombinant Human PLAT protein is just like all recombinant proteins. The process involved transfecting E.coli cells with DNA vector containing the template of recombinant DNA. The E.coli cells containing the template were then cultured so that they could transcribe and translate the PLAT protein. N-terminal 6xHis-SUMO tag was used in the process. The purity is 90% determined by SDS-PAGE.

PLAT is a gene providing instructions for making a protein named tissue-type plasminogen activator (also known as a t-plasminogen activator, tPA). This protein is a serine protease that converts a zymogen plasminogen into an active serine protease, namely, plasmin (the primary enzyme involved in dissolving blood clots). tPA is involved in blood coagulation, cellular protein modification process, fibrinolysis, response to hypoxia, smooth muscle cell migration and trans-synaptic signaling by BDNF, modulating synaptic transmission.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here


We would like to know the components of the buffer for item CSB-EP018120HU. Would you have this information on file that you could share?
Would the components of the buffer be the same if they ordered 10 mg?

Thanks for your inquiry. The Datasheet&COA is attached which includes the buffer components. We could guarantee 10mg from same lot, so the buffer components will be the same.

Target Background

Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in tissue remodeling and degradation, in cell migration and many other physiopathological events. During oocyte activation, plays a role in cortical granule reaction in the zona reaction, which contributes to the block to polyspermy.
Gene References into Functions
  1. These findings provides evidence that gene-gene interactions between p11, tPA and BDNF are all associated with post stroke depression. PMID: 29028593
  2. Underexpression of Tissue plasminogen activator is associated with diabetic foot syndrome. PMID: 28193577
  3. By mediating the tPA response in macrophages, the NMDA-R provides a pathway by which the fibrinolysis system may regulate innate immunity. PMID: 28684538
  4. Data suggest that protein aggregates interact with tissue-type plasminogen activator and plasminogen to efficiently generate plasmin; this aggregate-bound plasmin is shielded from inhibition by alpha-2-antiplasmin and degrades protein aggregates to release smaller, soluble but relatively hydrophobic peptide fragments; these fragments bind to and are cytotoxic to microglia (by not vascular endothelial cells). PMID: 28710283
  5. Altogether, this preclinical study demonstrates that the tPA present in the blood stream is a key player of the formation of intracranial aneurysms. PMID: 28754830
  6. tPA is a ligand of the N-terminal domain of the obligatory GluN1 subunit of NMDAR acting as a modulator of their dynamic distribution at the neuronal surface and subsequent signaling. PMID: 27831563
  7. t-PA binds to Lys91 in the MBP NH2-terminal region and PLGbinds to Lys122 in the MBP COOH-terminal region. This proximity promotes the activation of Pg by t-PA. PMID: 28648598
  8. local accumulation of cortisol is a causative factor for amnion epithelial apoptosis via activation of tPA/plasmin system toward the end of gestation. This may contribute to the ROM at both term and preterm birth. PMID: 27690691
  9. We identified a homozygous null mutation in PLAT that abrogated t-PA level in patient cells. This is the first reported human knockout mutation of PLAT. The apparent association with hydranencephaly, diaphragmatic hernia and postnatal lethality requires further validation. PMID: 27417437
  10. Tissue plasminogen activator (t-PA) antigen is a marker of cardiovascular risk. Exercise interventions associated with weight loss reduce t-PA antigen. Endurance training per se reduces t-PA antigen in healthy overweight men. PMID: 28254694
  11. we reviewed current knowledge of mechanisms by which tPA can influence brain function in physiological and pathological conditions--REVIEW} PMID: 26626577
  12. Data suggest that baseline levels of adiponectin, C-reactive protein, TPA, and fibrinogen or changes in these levels do not explain increased risk of diabetes type 2 in overweight women with glucose intolerance and histories of gestational diabetes. PMID: 25970741
  13. Tissue plasminogen activator (tPA) may be a general factor in the immunological response to viruses. PMID: 26704613
  14. tPA has a role in progression of periventricular white matter hyperintensities PMID: 26942412
  15. These data indicate that oxygen-glucose deprivation-triggered Cav-1 S-nitrosylation interacts with tPA-induced ERK activation to augment MMP2 and 9 secretion and subsequent extracellular matrix degradation. PMID: 26881424
  16. tPA-dependent activation of EGFRs leads to downregulation of NMDAR signaling and to subsequent neurotrophic effects. PMID: 26469972
  17. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalization may improve safety of thrombolytic therapy. PMID: 25855589
  18. Intravenous tissue plasminogen activator therapy was associated with improved clinical outcomes without significant increase in risk of hemorrhagic complications in very old patients (aged>80 years) with acute ischemic stroke. PMID: 25329379
  19. Review: t-PA function and regulation of its pericellular activity, with an emphasis on regulation of its gene expression. PMID: 24718307
  20. data implicate MCP-1 as the key molecule governing tPA-induced fluid accumulation. The role of MCP-1 in the development of other exudative effusions warrants examination. PMID: 25474480
  21. remarkable association especially between the -1131C Apo A5 variant and increased tPA levels in asymptomatic dyslipidemic patients PMID: 24815086
  22. The results suggest roles for TLR3, TLR10, PLAT (n=2), VEGFA and DENND1B in susceptibility to chronic cavitary pulmonary aspergillosis. PMID: 24712925
  23. shRNA-mediated silencing of PLAT in glioma-initiating cells phenocopied the effects of miR340 overexpression in vitro effects of miR340 overexpression in vitro PMID: 25627976
  24. Activation of T cells triggered a rapid, 8.4-fold up-regulation of the serine protease tissue plasminogen activator, the protease target for neuroserpin. PMID: 25670787
  25. Report tPA with a cutoff of 8.5 ng/mL has a high sensitivity and negative predictive value for exclusion of pulmonary embolism. PMID: 25339163
  26. Data indicate that binding of tissue-type plasminogen activator (t-PA) to glucose-regulated protein 78 (GRP78) stimulates its amidolytic activity, activation of plasminogen (Pg), and cell proliferation. PMID: 25059665
  27. Obese men exhibited lower levels of TPA activity compared to normal weight men. PMID: 25306554
  28. plasminogen and plasmin but not tissue-type plasminogen activator have roles in regulating fibrinolysis by C-terminal lysines PMID: 22974122
  29. It is involved in Amyloid-beta catabolism and clearance, which is particularly efficient for degrading Amyloid-beta aggregates. Thus, endogenous tPA could delay Alzheimer's disease pathogenesis by maintaining low levels of brain Amyloid beta. PMID: 24126163
  30. Data suggest that tPA is required for bone repair and osteoblast proliferation; recombinant tPA stimulates proliferation of osteoblastic cell line. PMID: 24918201
  31. Endogenously released tPA promotes neutrophil transmigration to reperfused tissue via proteolytic activation of plasmin and gelatinases. PMID: 24764453
  32. There are correlations between t-PA, PAI-1 and some rotational thromboelastometry parameters in multiple myeloma patients. PMID: 24964508
  33. Identify 3 loci associated with circulating tPA levels, the PLAT region, STXBP5, and STX2. Functional studies implicate a novel role for STXBP5 and STX2 in regulating tPA release. PMID: 24578379
  34. Studies suggest that inadequate synthesis and release of tissue plasminogen activator (tPA) or low tPA activity be considered a critical component of schizophrenia pathophysiology. PMID: 24108470
  35. Tissue plasminogen activator (t-PA) is a model of preterm intracerebral-intraventricular hemorrhages for the ontogenic window of vascular immaturity and protection against later neurodisabilities. PMID: 24709679
  36. Data suggest plasma tissue plasminogen activator (t-PA) and fibrin fragment D-dimer levels are higher in abdominal aortic aneurysm patients than in controls; however, there is a negative relationship between t-PA and intraluminal thrombus thickness. PMID: 23959729
  37. LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. PMID: 24129569
  38. Renal impairment is associated with higher risk of symptomatic intracranial hemorrhage (sICH) after administration of intravenous tPA. PMID: 24145699
  39. Successful thrombolysis can resolve DWI lesions but does not always improve the neurological symptoms. PMID: 21848677
  40. Excess tissue-type plasminogen activator causes targeted Purkinje cell degeneration and ataxia. PMID: 23939410
  41. II genotype carrier osteomyelitis patients had lower PAI-1/tPA complex levels. PMID: 23570848
  42. Intravenous thrombolysis with alteplase does not appear to increase the risk of hemorrhagic complications in these non-metastatic cancer patients, in absence of additional risk factors of bleeding. PMID: 23317922
  43. The combination of recombinant PA and erythropoietin increases release of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) and thereby potentially deteriorates ischemic stroke outcome. PMID: 23788583
  44. Use of intraventricular tPA for aneurysmal subarachnoid hemorrhage surgery results in less vasospasm, fewer angioplasties, and fewer cerebrospinal fluid shunting procedures. PMID: 20559098
  45. Persons who develop non-affective psychoses have lower levels of certain acute phase proteins, including tPA, at the time of birth. PMID: 23423137
  46. This meta-analysis suggested that the -7351C/T polymorphism in TPA gene would be a risk factor for ischemic stroke. PMID: 23326456
  47. These results suggest that retained tPA on vascular endothelial cells effectively activated plasminogen to plasmin. PMID: 23118500
  48. The serine protease tissue plasminogen activator (tPA) and two matrix metalloproteinases, ADAMTS-4 and ADAMTS-5, were identified as Reelin cleaving enzymes. PMID: 23082219
  49. Intraventricular fibrinolysis with recombinant tPA does not lead to increased perihemorrhagic edema after intracerebral hemorrhage. PMID: 23306318
  50. VDAC binds tissue-type plasminogen activator (t-PA) on human neuroblastoma SK-N-SH cells PMID: 23161549

Show More

Hide All

Involvement in disease
Increased activity of TPA results in increased fibrinolysis of fibrin blood clots that is associated with excessive bleeding. Defective release of TPA results in hypofibrinolysis that can lead to thrombosis or embolism.
Subcellular Location
Secreted, extracellular space.
Protein Families
Peptidase S1 family
Tissue Specificity
Synthesized in numerous tissues (including tumors) and secreted into most extracellular body fluids, such as plasma, uterine fluid, saliva, gingival crevicular fluid, tears, seminal fluid, and milk.
Database Links

HGNC: 9051

OMIM: 173370

KEGG: hsa:5327

STRING: 9606.ENSP00000220809

UniGene: Hs.491582

CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details


II. Contact details


III. Ship To


IV. Bill To